Maze Therapeutics, Inc. · NASDAQ:MAZE
Maze Therapeutics — Q4 2025 Earnings Presentation
27 slides from Maze Therapeutics's earnings presentation, Mar 25, 2026
Slide 1: Maze Therapeutics: MZE829 HORIZON Phase 2 Topline Data
Maze Therapeutics Harnessing the power of human genetics to transform the lives of patients MZE829 – Oral APOL1 Inhibitor For APOL1-Mediated Kidney Disease (AMKD) HORIZON Phase 2 Topline Data March 25, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements oth
Slide 3: Today’s Presenters
Today’s Presenters JASON COLOMA, Ph.D. HAROLD BERNSTEIN, M.D., Ph.D. Chief Executive Officer President, Research & Development and Chief Medical Officer 3
Slide 4: Agenda
Agenda Introduction Jason Coloma, Ph.D. Chief Executive Officer MZE829 Phase 2 Data Harold Bernstein, M.D., Ph.D. President of Research & Development, Chief Medical Officer Closing Remarks Jason Coloma, Ph.D. Chief Executive Officer Q&A 4
Slide 5: Introduction
Introduction
Slide 6: Maze Therapeutics: Harnessing the power of human genetics
Maze Therapeutics: Harnessing the power of human genetics to transform the lives of patients Clinical-stage biopharma Kidney & Cutting-Edge Novel small molecule Metabolic Genetics precision medicines Disease Expected cash runway into 2028 6
Slide 7: Focused Pipeline in Kidney & Metabolic Diseases
Focused Pipeline in Kidney & Metabolic Diseases Target Lead Anticipated Program Target Indication Validation Optimization IND-Enabling Phase 1 Phase 2 Phase 3 Catalysts APOL1-mediated Positive topline MZE829 APOL1 Kidney Disease Phase 2 enrolling data Q1 2026 (AMKD) Initiate Phenylketonuria Phase 2
Slide 8: Broad AMKD Represents Significant Need
Broad AMKD Represents Significant Need At least 250,000 Estimated AMKD patients in U.S. Diabetics Hypertensive Non-Diabetics Other CKD (e.g. SLE, SCN, HIVAN)1 FSGS No approved therapies currently exist for AMKD despite its prevalence and severity 1. SLE = systemic lupus erythematosus HIVAN = HIV-ass
Slide 9: MZE829 Dual Mechanism: Disrupts APOL1 Pore Assembly and Inhibits Pore Function
MZE829 Dual Mechanism: Disrupts APOL1 Pore Assembly and Inhibits Pore Function APOL1-Driven Podocyte Death and Kidney Damage MZE829 Dual Mechanism of Action Increased number of toxic pores MZE829 blocks MZE829 blocks 1 2 Toxic APOL1 pores are disrupts podocyte function and pore formation pore functi
Slide 10: ≥30% average uACR reduction is clinically meaningful
≥30% average uACR reduction in broad AMKD is broadly accepted as clinically meaningful and would demonstrate clinical PoC ≥30% uACR1 Reduction Correlated with eGFR slope improvement and 10-year delay to ESKD2 Used in practice (e.g., KDIGO guidelines3) Validated surrogate endpoint for CKD drug develo
Slide 11: Positive Results
Positive Results
Slide 12: HORIZON: Best-in-Class AMKD Potential for MZE829
HORIZON: Best-in-Class AMKD Potential for MZE829 36% 62% 50% Favorable Mean uACR Reduction1 Mean uACR Reduction1 Achieved ≥30% Response3 Safety Profile Broad AMKD FSGS2 without diabetes 49% Early promising results in AMKD patients with diabetes; enrollment continues Maze to advance MZE829 into a piv
Slide 13: MZE829 Phase 2 Topline Data
MZE829 Phase 2 Topline Data
Slide 14: MZE829 Phase 2 HORIZON in Patients with AMKD
MZE829 Phase 2 HORIZON in Patients with AMKD Open-label basket study in adults with proteinuric chronic kidney disease (CKD) and APOL1 high-risk genotype Patient Timeline Stable SoC1 required for at least 8 weeks prior to screening N=8 Non-Diabetics N = 15 N =7 Diabetics Screening Treatment Period F
Slide 15: Demographics Overview
Demographics Overview AMKD without AMKD with Total AMKD Characteristic diabetes diabetes (N=15) 1 (N=8) (N=7) Age — yr 49.1±12.0 46.4±13.4 52.3±10.3 Sex — no. (%) Female 7 ( 46.7) 4 ( 50.0) 3 ( 42.9) Male 8 ( 53.3) 4 ( 50.0) 4 ( 57.1) APOL1 genotype — no. (%) G1/G1 3 (20.0) 1 (12.5) 2 (28.6) G2/G2 9
Slide 16: Most patients had moderate proteinuria, reflecting a broad AMKD population
Most patients had moderate proteinuria, reflecting a broad AMKD population MILD MODERATE SEVERE HORIZON cut-off 2 Patients 3 Patients 10 Patients Proteinuria Levels <30 300 1000 ≥2200 3000+ uACR mg/g1 Nephrotic range 1. uACR at baseline was calculated as mean of 3 consecutive first morning voids dur
Slide 17: Safety Overview – Key Takeaways
Safety Overview – Key Takeaways MZE829 well-tolerated and consistent with Ph 1 safety profile • No Serious Adverse Events (SAEs) • 5 patients had treatment-related adverse events (TRAEs): all mild or moderate • One patient had a TRAE leading to treatment discontinuation due to mild nausea • No clini
Slide 18: Summary of Adverse Events
Summary of Adverse Events AE Category Total AMKD Non-Diabetic Diabetic no. (%) (N=15)1 (N=8) (N=7) Adverse event 10 (66.7) 6 (75.0) 4 (57.1) TEAE based on severity 10 (66.7) 6 (75.0) 4 (57.1) Mild 5 (33.3) 4 (50.0) 1 (14.3) Moderate 4 (26.7) 2 (25.0) 2 (28.6) Severe 1 (6.7) 0 1 (14.3) Treatment-rela
Slide 19: MZE829 demonstrates clinical proof-of-concept in moderate AMKD patients
MZE829 demonstrates clinical proof-of-concept in moderate AMKD patients AMKD Patients with and without Diabetes 35% Without Diabetes With Diabetes Mean uACR reduction for both 15% cohorts at 12 weeks: 36%2 Mean % change in uACR1 -5% * Response rate at ≥30% uACR -25% * reduction: 50%2 -45% ≥30% reduc
Slide 20: AMKD Patients without Diabetes: Mean uACR Change
49% Mean uACR Reduction at 12 Weeks AMKD Patients without Diabetes 15% 5% -5% Mean uACR reduction in patients Mean % change in uACR 1 -15% without diabetes at 12 weeks: 49%2 -25% * -35% Response rate at ≥30% uACR reduction: 57%2 -45% * -55% * Mean uACR reduction in FSGS -65% subset: 62%2 -75% * Indi
Slide 21: Promising early data in AMKD patients with diabetes
Promising early data in AMKD patients with diabetes G2/G2 G1/G2 Patient with Patient with Early Disease Onset Multiple Comorbidities • 37-year-old male • Type 2 diabetes • 63-year-old male • Type 2 diabetes • Hyperlipidemia • Stage 2 CKD • Hypertension • Stage 3 CKD • Hypertension • Hyperparathyroid
Slide 22: Summary of data: MZE829 demonstrates clinical proof-of-concept
Summary of data: MZE829 demonstrates clinical proof-of-concept • MZE829 Clinical Proof-of-Concept: 1st clinical study in genetically defined, broad AMKD population, including patients with less severe proteinuria and diabetes • Favorable Safety Profile: Generally well-tolerated with no serious adver
Slide 23: Closing Remarks
Closing Remarks
Slide 24: Recent announcements reinforce Maze Compass platform validation
Recent company-related announcements reinforce continued Maze CompassTM platform validation Positive HORIZON data in Broad AMKD and advancing to a pivotal program MZE782 advancement to two Phase 2 trials with best-in-class potential in PKU and potential first-in-class opportunity in CKD 3 clinical p
Slide 25: HORIZON: Best-in-Class AMKD Potential for MZE829
HORIZON: Best-in-Class AMKD Potential for MZE829 36% 62% 50% Favorable Mean uACR Reduction1 Mean uACR Reduction1 Achieved ≥30% Response3 Safety Profile Broad AMKD FSGS2 without diabetes 49% Early promising results in AMKD patients with diabetes; enrollment continues Maze to advance MZE829 into a piv
Slide 26: Q&A
Q&A
Slide 27: uPCR: MZE829 demonstrates clinical proof-of-concept in moderate AMKD patients
UPCR: MZE829 demonstrates clinical proof-of-concept in moderate AMKD patients AMKD Patients with and without Diabetes 35% Without Diabetes With Diabetes Mean uPCR reduction for both cohorts at 12 weeks: 31%2 15% Mean % change in uPCR1 Mean uPCR reduction in patients -5% without Diabetes at 12 weeks: